Consolidated Statements of Cashflows - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net loss	$ (14,710,460)	$ (34,268,912)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of derivative liabilities	451,351	685,415
Change in derivative liability for authorized shares shortfall	170,319,590	18,921,537
Depreciation and amortization		45,282
Interest and amortization of debt discount	5,139,321	4,716,970
(Gain) loss on conversion of convertible notes payable	(882)	603,529
Gain on settlement of convertible notes payable and accrued interest, warrants and accounts payable	(162,109,131)
Gain on forgiveness of debt	(250,000)
Stock-based compensation		222,700
Impairment on COWA advances		360,500
Impairment of investment		65,000
Loss on sale of investment in Canna Regs		91,931
Impairment loss on software costs		196,315
Preferred stock issuance costs		5,585,594
Changes in operating assets and liabilities:
Prepaid expenses	(95,157)	12,025
Advance to COWA, net		(360,500)
Security deposit		36,000
Accounts payable and accrued expenses	77,520	557,360
Accrued payroll and related expenses	140,005	732,027
Net cash used in operating activities	(1,037,843)	(1,797,227)
Cash flows from investing activities:
Proceeds from sale of Reg Tech and High Times		90,981
Net cash provided by investing activities		90,981
Cash flows from financing activities:
Bank overdrafts	(13,749)	13,749
Proceeds from sale of Series X preferred shares	321,000
Proceeds from sale of Series B preferred shares and warrants		1,407,500
Proceeds from exercise of warrants		172,949
Proceeds from issuance of convertible notes payable	637,000	549,000
Proceeds from issuance of non-convertible notes payable	82,911	175,000
Repayment of non-convertible notes payable	(39,641)	(45,400)
Proceeds from advances	3,696
Proceeds from PPP note payable	50,000
Repayments of advances	(3,009)	(595,000)
Net cash provided by financing activities	1,038,208	1,677,798
Net increase (decrease) in cash	365	(28,448)
Cash, beginning of year	1,120	29,568
Cash, end of year	1,485	1,120
Supplemental disclosures of cash flow information:
Cash paid during period for interest		218,500
Cash paid during period for taxes
Supplemental disclosure of non-cash investing and financing activities:
Issuance of common stock previously to be issued	37,160	80
Issuance of preferred Series A shares in exchange for warrants canceled		296,746
Conversions of preferred Series A shares to common shares		3,137,248
Common stock issued as origination shares		141,333
Common stock issued upon conversion of convertible notes and accrued interest	370,755	1,732,318
Common shares contributed back to the Company and promptly retired	69
Common stock issued in settlement of a warrant provision		437,400
Common stock issued in exercise of cashless warrants		3,998
Deemed dividend related to warrant price protection	95,838,488	28,933,472
Contingent beneficial conversion feature on preferred Series A shares		45,147,093
Deemed dividend resulting from exchange of preferred Series A and Series B shares for convertible notes		1,476,280
Preferred Series B shares exchanged for convertible notes		$ 826,884
Convertible note payable issued to CFO with BCF	64,143
Derivative liability recognized as debt discount on newly issued convertible notes	573,230
Series Y preferred shares issued as settlement for convertible notes payable, accrued interest and warrants	13,095,636
Amortization of discount on preferred stock	1,074,539
Reclassify accrued interest to convertible notes payable	1,049,329
Recission of warrants exercised in prior year	$ 6,000